Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Merck

Januvia, Janumet, Isentress, and Gardasil see double-digit growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck

4Q Revenues: $12.3 billion (+2%)

4Q Earnings: $1.5 billion (loss of $531 million 4Q10)

FY Revenues: $48.0 billion (+4%)

FY Earnings: $6.3 billion (earnings were $982 million FY10)

Comments: Pharmaceutical sales were $10.8 billion in the quarter (+3%) and $41.3 billion for the year (+5%). Singulair sales rose 8% to $1.5 billion in the quarter and $5.5 billion for the year (+10%). Januvia sales were up 42% in the quarter to $960 million and up 39% to $3.3 billion for the year. Janumet sales were up 34% in the quarter and 43% for the year to $386 million and $1.4 billion, respectively. Isentress sales were up 24% in the quarter and 25% for the year to $387 million and $1.4 billion, respectively. Gardasil sales were up 24% in the quarter to $274 million and up 22% for the year to $1.2 billion. Cozaar/Hyzaar sales were $427 million in the quarter (+3%) and $1.7 billion for the year (-21%) due to loss of exclusivity in the U.S. Remicade sales were down 28% in the quarter to $511 million and down 2% to $2.7 billion for the year, due to the July 2011 transfer of some exclusive marketing rights for Remicade and Simponi to Johnson & Johnson. Merck retained rights in Europe, Russia and Turkey. Vytorin sales were down 16% in the quarter to $475 million and down 7% for the year to $1.9 billion, related to certain safety concerns. Earnings in 2010 reflect the impact of acquisition-related costs, and restructuring costs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters